In the era of psoriasis treatment and biological agents, there are many giants, and Lilly new drug Tuozi is listed in China

In March 2016, taltz (Tuozi ®, iqzumab injection), a new generation anti-inflammatory drug of Lilly pharmaceutical, completed the largest phase III clinical trial based on the moderate to severe plaque psoriasis population, and obtained good data evidence After that, Talz (iqzumab injection) was approved by FDA for the treatment of adult patients with moderate to severe plaque psoriasis suitable for systematic treatment or phototherapy Attention of the international community Three years later, in September 2019, through the first batch of clinically urgent overseas new drug channels, Tuozi ® was approved by China National Drug Administration for listing in China It only took six months from the submission of listing application to the approval On November 7, Lilly Pharmaceutical (China) held the signing ceremony of business strategic partners and the listing meeting of Tuozi ® dealers during the second China International Fair, and reached a purchase intention of more than 3 billion RMB with 17 domestic drug distribution enterprises At the signing ceremony of business strategic partners and on-the-spot listing meeting of Tuozi dealers, Tuozi is an inhibitor targeting IL-17A, and the second monoclonal anti-inflammatory drug in the world For patients with psoriasis, IL-17A plays an important role in driving the excessive proliferation and activation of keratinocytes (skin cells) The results showed that Tuozi has high affinity and specificity for IL-17A, which can inhibit the binding of IL-17A to IL-17 receptor, and will not bind to IL-17B, il-17c, il-17d, il-17e or IL-17F Psoriasis is an immune-mediated chronic, recurrent, inflammatory and systemic disease induced by the interaction of genetics and environment Once it gets sick, it can not be cured At present, there are about 6.5 million psoriasis patients in China According to the World Health Organization (who) global report on psoriasis published in 2016, 93% of patients expect to achieve complete removal of skin lesions In the past, it was difficult for traditional treatment to achieve good and stable results, and many treatment needs of psoriasis patients in China could not be met In clinical practice, psoriasis can be divided into three types: drip type, plaque type and reverse type, erythroderma type, pustule type and arthropathy type, among which the first three types are collectively called psoriasis vulgaris in traditional treatment There is a huge gap in the etiology, clinical manifestations, treatment and prognosis of different types of psoriasis The occurrence and development of psoriasis will go through the process of light to heavy Taking plaque psoriasis as an example, in children, there is a long period of no skin lesions from the drip type to the plaque type, while in adults, there is a rapid transition from the drip type to the plaque type Early screening, early diagnosis and planned treatment are very important in the treatment of psoriasis According to Zheng Jie, the national leader of Tuozi ® phase I and phase III clinical research project in China, former chairman of Dermatology and Venereology branch of Chinese Medical Association, and professor of Dermatology Department of Ruijin Hospital Affiliated to Shanghai Jiaotong University Medical College, it is internationally recognized that the area and severity of skin lesions (PASI) are regarded as the evaluation standard of psoriasis treatment effect, and the PASI index is reduced by more than 75%, so the treatment is judged as having Effectiveness In other words, from the perspective of efficacy, there is no cure for psoriasis Traditionally, psoriasis is treated by oral and external use Before the 20th century, methotrexate, cyclosporine and tretinoin were the mainstream psoriasis drugs in the world Professor Zheng Jie pointed out that at present, methotrexate is still the main drug for psoriasis treatment in China Optimization of psoriasis treatment has always been a clinical need to be met On the one hand, the safety of traditional drugs is poor, and some patients are forced to stop because of serious side effects; on the other hand, the satisfaction and compliance of patients with traditional treatment programs are low According to Julio gay GER, President and general manager of Lilly China, Tuozi ® is administered by subcutaneous injection, and the patient can use it at home alone, with convenient operation Clinical data show that PASI of patients with plaque psoriasis can achieve a maximum of 100% improvement after using Tuozi ®, which leads to another evaluation standard of psoriasis treatment - Dermatology quality of life index (DLQI) increase Julio gay GER, President and general manager of Eli Lilly China, Professor Zhang Xuejun, director of the Institute of Dermatology, Fudan University, told aoli.com that long before Tuozi was officially approved for listing, researchers had included it in the Chinese psoriasis diagnosis and treatment guide based on previous results Psoriasis treatment entered the era of biological agents in 2004 Embrel (enacep), a moderate to severe rheumatoid arthritis drug of Amgen, was approved by FDA, increasing the indications of adult moderate to severe plaque psoriasis, thus opening the era of biological agents for psoriasis treatment Since then, infliximab (2006), adamumumab (2008), ulinumab (2009), and scuchiumab (2015) have been approved for the treatment of moderate and severe psoriasis Psoriasis, an ancient human disease, has become a new battlefield for multinational pharmaceutical giants such as Johnson & Johnson, Pfizer, and Aberdeen According to Professor Zheng Jie, up to now, the development of psoriasis has gone through three stages The first is tumor necrosis factor - α (TNF - α) inhibitors, which are only effective for some patients with psoriasis and are easy to relapse; the second is the biological agents that act on IL-23 and IL-12, which can effectively treat patients with ineffective treatment of TNF - α inhibitors; the third is the new type of monoclonal antibody of IL-17A, which is single IL-17A for patients with psoriasis who have ineffective treatment or relapse of the first two biological agents Anti therapy is effective "As the second monoclonal antibody of IL-17A in the world, topaz ® has made improvements in safety and effectiveness The treatment with treasurer's chiyoximab is ineffective or relapsed, and the continued use of topaz ® is still effective." Professor Zheng Jie said For this dealer meeting, Ji Liwen said: "we are honored to have the opportunity to participate in this fair China's ever opening huge market has injected growth momentum and precious confidence into global enterprises Lilly has always attached great importance to the Chinese market In the past year, we have 5 new products and 3 new indications approved In the future, we will actively introduce more innovative drugs In the next 10 years, we will also be able to market 40 new products in China, including new indications, to help support the Chinese government to achieve the great goal of "healthy China 2030" and bring good news to Chinese patients " Dr Wang Yizhe, senior vice president of Lilly China and head of anti-tumor products and cross biochemical products in China, said: "immune field is an important business field of Lilly in the future, covering rheumatism, dermatology and digestive tract diseases The rapid approval of Tuozi ® and its entry into the stage of the Expo reflect the importance Lilly attaches to this field At present, we are working closely with all sectors of society to care for thousands of psoriasis patients from drug innovation, service innovation, payment innovation and other dimensions In the future, Lilly will continue to enrich its autoimmune product line, actively plan its strategic layout, so as to bring more new products and new indications to China faster and bring more high-quality treatment options to Chinese patients " Dr Wang Yizhe, senior vice president of Lilly China and head of anti-tumor products and cross biochemical products in China, came to China in 1918 and set its first overseas representative office in Shanghai Over the past hundred years, Lilly has always adhered to the concept of "taking root in China and benefiting China" With the rapid pace of China's "opening up, integration and innovation", Lilly has focused on expanding its business in China, constantly practicing its innovation mission and continuously benefiting Chinese patients Over the past 40 years of reform and opening up, China has been committed to building an innovative and inclusive open world economy, and constantly put forward new measures to expand opening up The second China International Fair held in Shanghai is a global event, which not only shows China's commitment to promoting a new round of higher-level opening up, but also an important platform for multinational enterprises to display innovative products and expand market Since 2015, China has expanded opening up and encouraged innovation in the field of medicine, launched a series of institutional reforms to accelerate the review and approval of innovative drugs, with unprecedented strength and efficiency The theme of Lilly's exhibition is "innovation" The new psoriasis drug Tuozi ® (iqzumab injection) brought by Lilly is just the "Dongfeng" of the policy, so it can be listed in China in advance Penicillin is the reprinted content of yaozhi.com, and the copyright belongs to the original author The purpose of reprinting is to transmit more information, which does not represent the view of this platform If the content of the work, copyright and other issues are involved, please contact our website message, we will delete the content in the first time.